RA
DAWN

Rise Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Rise Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-69
Closed -$486 – 444
2025
Q3 		$486 Buy
+69
New +$475 ﹤0.01% 1423

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rise Advisors's DAWN Position: Q4 2025 in Review

Rise Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 69 shares — an estimated $486 sold.

Rise Advisors first reported a position in DAWN in Q3 2025 and held it in 1 quarter. The position peaked at $486 in Q3 2025. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Rise Advisors reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 69 Day One Biopharmaceuticals shares in Q4 2025, an estimated $486.
  • Rise Advisors first reported a position in Day One Biopharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Rise Advisors's Day One Biopharmaceuticals position peaked at $486 in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.